Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Nov 2021
Historique:
received: 03 10 2021
revised: 24 10 2021
accepted: 30 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

The incidence of depression among humans is growing worldwide, and so is the use of antidepressants. However, our fundamental understanding regarding the mechanisms by which these drugs function and their off-target effects against human sexuality remains poorly defined. The present study aimed to determine their differential toxicity on mouse spermatogenic cells and provide mechanistic data of cell-specific response to antidepressant and neuroleptic drug treatment. To directly test reprotoxicity, the spermatogenic cells (GC-1 spg and GC-2 spd cells) were incubated for 48 and 96 h with amitriptyline (hydrochloride) (AMI), escitalopram (ESC), fluoxetine (hydrochloride) (FLU), imipramine (hydrochloride) (IMI), mirtazapine (MIR), olanzapine (OLZ), reboxetine (mesylate) (REB), and venlafaxine (hydrochloride) (VEN), and several cellular and biochemical features were assessed. Obtained results reveal that all investigated substances showed considerable reprotoxic potency leading to micronuclei formation, which, in turn, resulted in upregulation of telomeric binding factor (TRF1/TRF2) protein expression. The TRF-based response was strictly dependent on p53/p21 signaling and was followed by irreversible G2/M cell cycle arrest and finally initiation of apoptotic cell death. In conclusion, our findings suggest that antidepressants promote a telomere-focused DNA damage response in germ cell lines, which broadens the established view of antidepressants' and neuroleptic drugs' toxicity and points to the need for further research in this topic with the use of in vivo models and human samples.

Identifiants

pubmed: 34769286
pii: ijms222111855
doi: 10.3390/ijms222111855
pmc: PMC8584852
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Antipsychotic Agents 0
TRF2 protein, mouse 0
Telomeric Repeat Binding Protein 1 0
Telomeric Repeat Binding Protein 2 0
Fluoxetine 01K63SUP8D
Amitriptyline 1806D8D52K
Escitalopram 4O4S742ANY
Venlafaxine Hydrochloride 7D7RX5A8MO
Reboxetine 947S0YZ36I
Mirtazapine A051Q2099Q
Olanzapine N7U69T4SZR
Imipramine OGG85SX4E4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Science Center
ID : UMO-2014/15/N/NZ7/04097

Références

World J Gastrointest Oncol. 2014 Jan 15;6(1):11-21
pubmed: 24578784
Cell Death Dis. 2013 Jul 04;4:e713
pubmed: 23828576
Lancet Psychiatry. 2016 Feb;3(2):95-6
pubmed: 26777772
FEBS Lett. 2005 Sep 12;579(22):5105-10
pubmed: 16139271
Neuropsychopharmacology. 2018 Jan;43(2):445-453
pubmed: 28621334
Mol Pharmacol. 2011 Apr;79(4):672-80
pubmed: 21220410
J Affect Disord. 2016 Feb;191:237-47
pubmed: 26688493
J Urol. 2008 Nov;180(5):2124-8
pubmed: 18804223
Basic Clin Pharmacol Toxicol. 2013 Nov;113(5):339-46
pubmed: 23759069
Int J Impot Res. 2008 Jul;20 Suppl 1:S17-23
pubmed: 18552830
Eur J Pharmacol. 2006 Jul 10;541(1-2):17-23
pubmed: 16753142
PLoS One. 2010 Dec 20;5(12):e15583
pubmed: 21187925
Int J Neuropsychopharmacol. 2007 Dec;10 Suppl 1:S1-207
pubmed: 18096106
Pharmacol Biochem Behav. 2014 Jun;121:132-7
pubmed: 24239785
Asian J Androl. 2014 Jan-Feb;16(1):31-8
pubmed: 24369131
Cancer Biol Ther. 2008 Oct;7(10):1685-93
pubmed: 18836303
Turk J Biol. 2018 Oct 25;42(5):414-421
pubmed: 30930625
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):92-100
pubmed: 22019604
J Clin Med. 2019 Oct 07;8(10):
pubmed: 31591339
Exp Toxicol Pathol. 2017 Oct 2;69(8):564-574
pubmed: 28552630
Cell. 2021 Mar 4;184(5):1299-1313.e19
pubmed: 33606976
Nature. 2011 Mar 24;471(7339):504-7
pubmed: 21430778
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
Curr Biol. 2015 May 4;25(9):1146-56
pubmed: 25913401
PLoS One. 2013 Oct 07;8(10):e76286
pubmed: 24116100
Asian J Androl. 2017 Nov-Dec;19(6):672-679
pubmed: 27976631
Patient Prefer Adherence. 2016 Jul 28;10:1401-7
pubmed: 27528803
Oncotarget. 2017 Jan 10;8(2):3181-3196
pubmed: 27911858
Cell Signal. 2005 May;17(5):549-57
pubmed: 15683730
Biol Cell. 2009 Jul 31;101(10):587-98
pubmed: 19419345
Drug Healthc Patient Saf. 2010;2:141-50
pubmed: 21701626
Front Biosci (Elite Ed). 2012 Jan 01;4:746-54
pubmed: 22201910
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6210-5
pubmed: 20308578
J Clin Med. 2019 Mar 14;8(3):
pubmed: 30875818
Drug Chem Toxicol. 2012 Oct;35(4):450-5
pubmed: 22251041
PLoS One. 2011;6(11):e27290
pubmed: 22076148
Philos Trans R Soc Lond B Biol Sci. 2010 May 27;365(1546):1501-15
pubmed: 20403866
Eur Rev Med Pharmacol Sci. 2012 Dec;16(15):2154-61
pubmed: 23280034
Mutat Res. 2009 Jan-Feb;681(1):3-12
pubmed: 18462987
CMAJ. 2006 Jan 17;174(2):193-200
pubmed: 16415467
J Biol Chem. 1999 Mar 5;274(10):6039-42
pubmed: 10037682
Biochem Pharmacol. 2008 May 15;75(10):1924-34
pubmed: 18371935
JAMA. 2017 Apr 18;317(15):1517
pubmed: 28418490
Ment Health Clin. 2016 Jun 29;6(4):191-196
pubmed: 29955469
Exp Cell Res. 2017 Jan 15;350(2):358-367
pubmed: 28011195
Oncotarget. 2016 Jul 19;7(29):46615-46627
pubmed: 27366950
Bioorg Med Chem Lett. 2006 May 1;16(9):2509-12
pubmed: 16464584

Auteurs

Przemysław Sołek (P)

Department of Biotechnology, Institute of Biology and Biotechnology, University of Rzeszow, Werynia 2, 36-100 Kolbuszowa, Poland.

Jennifer Mytych (J)

Department of Biotechnology, Institute of Biology and Biotechnology, University of Rzeszow, Werynia 2, 36-100 Kolbuszowa, Poland.

Anna Tabęcka-Łonczyńska (A)

Department of Biotechnology, Institute of Biology and Biotechnology, University of Rzeszow, Werynia 2, 36-100 Kolbuszowa, Poland.

Marek Koziorowski (M)

Department of Biotechnology, Institute of Biology and Biotechnology, University of Rzeszow, Werynia 2, 36-100 Kolbuszowa, Poland.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH